CYTEIR THERAPEUTICS, INC.
128 Spring St, Building A, Suite 510
Lexington, Massachusetts 02421
June 15, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Kasey Robinson, Tim Buchmiller, Division of Corporation Finance, Office of Life Sciences |
| Re: | Cyteir Therapeutics, Inc. |
Registration Statement on Form S-1 (File No. 333-256601)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date for the registration statement referred to above be accelerated so that it will be declared effective at 4:30 p.m. Eastern Time on June 17, 2021, or as soon as possible thereafter. The Company hereby authorizes Marc Rubenstein or Tara Fisher of Ropes & Gray LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
Please call Tara Fisher of Ropes & Gray LLP, counsel to the Company, at (617) 235-4824 as soon as the registration statement has been declared effective.
[Signature page follows]
| Very truly yours, | ||
| CYTEIR THERAPEUTICS, INC. | ||
| By: | /s/ Markus Renschler | |
| Name: | Markus Renschler, M.D. | |
| Title: | President and Chief Executive Officer | |
Signature Page to Acceleration Request
